Compounds and methods for inhibiting the interaction of BCL proteins with binding partners

1. A method of treating a bcl-mediated disorder selected from cancer and neoplastic disease, comprising the step of:

administering to a patient in need thereof a therapeutically effective amount of a compound of formula 1:

or a pharmaceutically acceptable salt thereof;

wherein independently for each occurrence

m is 0, 1, 2, or 3;

n, o, and p are independently for each occurrence 1, 2, 3, 4, or 5;

R 1 is —OH, —OC(O)R 6 , —OC(O)N(R 6 )(R 7 ), or —N(R 6 )(R 7 );

R 2 is —OH, —OC(O)Me, —OCH 2 CO 2 H, —OCH 2 CO 2 Et, —N 3 , —N(R 8 )(R 9 ), —N(R)C(O)N(R 8 )(R 9 ), or —N(R)C(O)R 10 ; or has the formula 1b;

R 3 is alkyl, halide, alkoxy,(cycloalkyl)alkoxy, aralkyloxy, or —O(CH 2 ) 2 —N(R 15 )(R 16 );

R 4 is alkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, halide, nitro, amino, acyl, amido, acylamino, aminoalkyl, acylaminoalkyl, acylaminoalkylamino, sulfonylaminoalkylamino, carboxylate, or —N═C(N(R) 2 ) 2 ;

R 5 is —OH or —N(R 17 )(R 18 );

R 6 and R 7 are independently for each occurrence H, alkyl, aralkyl, heteroaralkyl, or —[C(R 15 )(R 16 )] n —R 19 ;

R 8 and R 9 are independently for each occurrence H, alkyl, aralkyl, or heteroaralkyl;

R 10 is alkyl, haloalkyl, or —[C(R 15 )(R 16 )] o —COOR;

R, R 11 , R 12 , R 13 , R 14 , R 15 , and R 16 are independently for each occurrence H or alkyl;

R 17 and R 18 are independently for each occurrence H, alkyl, aralkyl, heteroaralkyl, alkoxy, or —[C(R 19 )(R 20 )] p —R 21 ;

R 19 and R 20 are independently for each occurrence H, hydroxy, alkyl, alkoxy, amino, aminoalkyl, acylamino, sulfonylamino, aryl, aralkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroaralkyl;

R 21 is independently for each occurrence H, alkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkoxy, alkylsulfonyl, arylsulfonyl, alkylsulfonamido, arylsulfonamido, amino, amido, or carboxyl;

R 22 independently for each occurrence is halide or alkyl;

R 23 is selected from the group consisting of alkyl, hydroxyalkyl, alkoxyalkyl, acyloxyalkyl, and haloalkyl;

R 24 is selected from the group consisting of alkyl, hydroxyalkyl, alkoxyalkyl, acyloxyalkyl, and haloalkyl; and

R 25 is selected from the group consisting of alkyl, hydroxyalkyl, alkoxyalkyl, acyloxyalkyl, and haloalkyl.

2. The method of claim 1 , wherein the bcl-mediated disorder is cancer.

3. The method of claim 1 , wherein the bcl-mediated disorder is neoplastic disease.

4. The method of claim 1 , wherein the bcl-mediated disorder is selected from the group consisting of acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, chronic leukemia, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, polycythemia vera, Hodgkin's disease, non-Hodgkin's disease; multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, uterine cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, and endometrial cancer.

5. The method of claim 2 , wherein the cancer is follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, prostate cancer, breast cancer, neuroblastoma, colorectal cancer, endometrial cancer, ovarian cancer, lung cancer, hepatocellular carcinoma, multiple myeloma, head and neck cancer, or testicular cancer.

6. The method of claim 2 , wherein the cancer exhibits a t(14;18) chromosomal translocation.

7. The method of claim 2 , wherein the cancer over-expresses a Bcl protein.

8. The method of claim 2 , wherein the cancer is dependent upon a Bcl protein for growth and survival.

9. The method of claim 7 or 8 , wherein the Bcl protein is Bcl-2.

10. The method of claim 7 or 8 , wherein the Bcl protein is Bcl-xL.

11. A method of treating a bcl-mediated disorder selected from cancer and neoplastic disease, comprising the step of:

co-administering to a patient in need thereof a therapeutically effective amount of at least one chemotherapeutic agent; and a therapeutically effective amount of a compound of formula 1:

or a pharmaceutically acceptable salt thereof;

wherein independently for each occurrence

m is 0, 1, 2, or 3;

n, o, and p are independently for each occurrence 1, 2, 3, 4, or 5;

R 1 is —OH, —OC(O)R 6 , —OC(O)N(R 6 )(R 7 ), or —N(R 6 )(R 7 );

R 2 is —OH, —OC(O)Me, —OCH 2 CO 2 H, —OCH 2 CO 2 Et, —N 3 , —N(R 8 )(R 9 ), —N(R)C(O)N(R 8 )(R 9 ), or —N(R)C(O)R 10 ; or has the formula 1b;

R 3 is alkyl, halide, alkoxy, (cycloalkyl)alkoxy, aralkyloxy, or —O(CH 2 ) 2 —N(R 15 )(R 16 );

R 4 is alkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, halide, nitro, amino, acyl, amido, acylamino, aminoalkyl, acylaminoalkyl, acylaminoalkylamino, sulfonylaminoalkylamino, carboxylate, or —N═C(N(R) 2 ) 2 ;

R 5 is —OH or —N(R 17 )(R 18 );

R 6 and R 7 are independently for each occurrence H, alkyl, aralkyl, heteroaralkyl, or —[C(R 15 )(R 16 )] n —R 19 ;

R 8 and R 9 are independently for each occurrence H, alkyl, aralkyl, or heteroaralkyl;

R 10 is alkyl, haloalkyl, or —[C(R 15 )(R 16 )] o —COOR;

R, R 11 , R 12 , R 13 , R 14 , R 15 , and R 16 are independently for each occurrence H or alkyl;

R 17 and R 18 are independently for each occurrence H, alkyl, aralkyl, heteroaralkyl, alkoxy, or —[C(R 19 )(R 20 )] p —R 21 ;

R 19 and R 20 are independently for each occurrence H, hydroxy, alkyl, alkoxy, amino, aminoalkyl, acylamino, sulfonylamino, aryl, aralkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroaralkyl;

R 21 is independently for each occurrence H, alkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl, alkoxy, alkylsulfonyl, arylsulfonyl, alkylsulfonamido, arylsulfonamido, amino, amido, or carboxyl;

R 22 independently for each occurrence is halide or alkyl;

R 23 is selected from the group consisting of alkyl, hydroxyalkyl, alkoxyalkyl, acyloxyalkyl, and haloalkyl;

R 24 is selected from the group consisting of alkyl, hydroxyalkyl, alkoxyalkyl, acyloxyalkyl, and haloalkyl; and

R 25 is selected from the group consisting of alkyl, hydroxyalkyl, alkoxyalkyl, acyloxyalkyl, and haloalkyl.

12. The method of claim 1 or 11 , wherein the patient is a mammal.

13. The method of claim 12 , wherein the patient is a primate.

14. The method of claim 13 , wherein the patient is a human.